You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD4 T cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Idiopathic CD4 T Cell Lymphocytopenia Trial run by the NIAID (Gardasil 9)

Recruiting
  • Idiopathic CD4 T Cell Lymphocytopenia
  • Gardasil 9
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 10, 2023

Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies Trial in Duarte (Cyclophosphamide, Pentostatin, Rabbit

Recruiting
  • Sickle Cell Disease
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jul 6, 2022

Optimising Cohorts for HIV Cure Interventions

Recruiting
  • HIV-1-infection
  • no intervention
  • Prahran, Victoria, Australia
    Alfred Health
May 1, 2023

Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +4 more
  • (no location specified)
Oct 23, 2023

T-cell Lymphoma, T-cell Leukemia Trial in Indianapolis (CD4CAR)

Recruiting
  • T-cell Lymphoma
  • T-cell Leukemia
  • CD4CAR
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
Dec 16, 2022

Chronic Myelomonocytic Leukemia Trial in Indianapolis (CD4CAR)

Not yet recruiting
  • Chronic Myelomonocytic Leukemia
  • CD4CAR
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
Oct 2, 2023

Multiple Sclerosis, Clinically Isolated Syndrome Trial in Bordeaux (blood sample, cerebro-spinal fluid)

Recruiting
  • Multiple Sclerosis
  • Clinically Isolated Syndrome
  • blood sample
  • cerebro-spinal fluid
  • Bordeaux, France
    CHU de Bordeaux - service de neurologie
Feb 2, 2022

Idiopathic CD4-Positive, T-Lymphocytopenia Trial run by the National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting
  • Idiopathic CD4-Positive
  • T-Lymphocytopenia
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 21, 2023

T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • +3 more
  • Universal CD7-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 17, 2023

Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 13, 2023

Celiac Disease Trial in Boston (Gluten powder 4g)

Completed
  • Celiac Disease
  • Gluten powder 4g
  • Boston, Massachusetts
  • +1 more
May 5, 2022

Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in

Suspended
  • Juvenile Myelomonocytic Leukemia
  • +27 more
  • CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2023

Interleukins in Periodontal Disease Progression

Recruiting
  • Periodontitis
  • Gingivitis
  • Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA
  • Assiut, Asyut, Egypt
    Department of oral medicine, Periodontology, Oral diagnosis and
Nov 16, 2023

B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

Recruiting
  • B Cell Malignancies
  • Universal CD19-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 12, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

Immune Response in Hypersensitivity Pneumonitis

Completed
  • Hypersensitivity Pneumonitis
  • Bronchoscopy with lavage
  • Iowa City, Iowa
    University of Iowa
May 16, 2022

T Cell Lymphoma, T-cell Leukemia Trial in Beijing (Efficacy of LCAR-T2C CAR-T cells)

Terminated
  • T Cell Lymphoma
  • T-cell Leukemia
  • Efficacy of LCAR-T2C CAR-T cells
  • Beijing, Beijing, China
  • +1 more
Aug 12, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/70 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 28, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/22 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/22 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 21, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/79b T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/79b T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 28, 2022

T-cell Lymphoma Trial (CHOP + CD4, CHOP)

Terminated
Has Results
  • T-cell Lymphoma
  • (no location specified)
May 2, 2022

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 30, 2022

T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory Trial in United States (LB1901)

Active, not recruiting
  • T-Cell Lymphoma
  • +4 more
  • LB1901
  • Rochester, Minnesota
  • +3 more
Feb 15, 2022